PDCI is very pleased to welcome Keeley Farrell to the PDCI Team as Analyst, HTA and Clinical Evaluation.
Keeley will help to support the development and preparation of the evidence-based clinical components of reimbursement and pricing submissions. She will also conduct research to support market access and ... Read More
25
Oct2019
22
Oct2019
PDCI presented a case study on the proposed amendments to the PMPRB regulations in Canada at the 2019 CAPT Conference held by the Canadian Association for Population Therapeutics.
The objective of this policy analysis was to estimate the impact of the proposed PMPRB amendments on orphan drug prices.
Review our poster ... Read More
12
Sep2019
REGISTRATION IS OPEN!
Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement
Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members of the PDCI team ... Read More
28
Aug2019
PDF Download: Gene Therapy Pathway
04
Jul2019
PDCI Market Access Inc. is pleased to announce a new Strategic Partnership with Goeree Consulting Ltd (owned and operated by Ron Goeree). Goeree Consulting and PDCI are bringing together an exceptional level of experience and expertise in health economics, while further expanding ... Read More
14
Jun2019
Mark down June 26th, 2019 in your calendars.
It is now widely expected the patented medicines price regulations will be in Canada Gazette Part II (CGII), volume 151 No.13, which will be released on June 26th. Draft PMPRB Guidelines for consultation will likely be published immediately following CGII publication. Comments earlier this week from Federal Health Minister Petitpas-Taylor, appeared to confirm these expectations. When asked in an interview surrounding when changes to the ... Read More
04
Jun2019
Article by PDCI Market Access featured in TELUS Health Insights Magazine
Members of the PDCI Team recently published an article and case study highlighting the risks to Canadian drug launches posed by Health Canada’s proposed Patented Medicines Prices Review Board (PMPRB) price regulatory reforms. This article, which appears in the Spring ... Read More
02
May2019
PDCI is very pleased to welcome Julia Shen to the PDCI Team as Associate, Corporate Marketing and Policy Research, effective April 23, 2019! Ms. Shen’s addition to the team reflects PDCI’s focus on continued growth with our current and new clients and our objective to expand services responding to the ... Read More
01
Apr2019
We are very pleased to announce that Helena Koa has joined PDCI as Manager, Market Access, effective today, April 1, 2019! Helena brings a wealth of knowledge and multi-disciplinary insights to PDCI: new product development, pricing and reimbursement, clinical research, health economics, and budget impact analyses. Helena’s experience spans over ... Read More
22
Mar2019
PDCI is very excited to announce the promotion of Jennifer Haig to the position of Associate Director, HTA and Health Economics. This promotion is effective immediately.
Jen has been with PDCI for 18 months, and in that time has ... Read More